help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on March 25, 2008
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2007-2792
A more recent version of this article appeared on June 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
93/6/2234    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Machens, A.
Right arrow Articles by Dralle, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Machens, A.
Right arrow Articles by Dralle, H.
Related Collections
Right arrow Thyroid
Right arrow Endocrine Oncology

Submitted on December 19, 2007
Accepted on March 19, 2008

Medullary Thyroid Cancer Responsiveness to Pentagastrin Stimulation: An Early Surrogate Parameter of Tumor Dissemination?

Andreas Machens MD*, Steffen Hauptmann MD, and Henning Dralle MD

Departments of General, Visceral and Vascular Surgery, and Pathology, Martin Luther University Halle-Wittenberg, D-06097 Halle (Saale), Germany

* To whom correspondence should be addressed. E-mail: AndreasMachens{at}aol.com.

Context: Because of its outstanding sensitivity, stimulation of calcitonin secretion with intravenous injection of pentagastrin is widely used for biochemical diagnosis of medullary thyroid cancer.

Objective: The objective of this study was to explore the relationship between the results of the pentagastrin stimulation test and extent of disease in patients with previously untreated medullary thyroid cancer.

Design: This was a retrospective study.

Setting: The investigation took place at a tertiary referral center.

Patients: Included were 89 patients with increased basal calcitonin levels who had a pentagastrin test at this institution before initial neck surgery for medullary thyroid cancer.

Main Outcome Measure: Measurements included basal and stimulated calcitonin levels, carcinoembryonic antigen (CEA) levels, primary tumor diameter, extrathyroidal extension, lymph node metastases, and distant metastases.

Results: There was a strong dose-dependent relationship between a less than 10-fold increase in preoperative calcitonin levels after intravenous stimulation with pentagastrin and both the frequency (41–54% vs. 4–27%; P<0.001) and number (means of 3.0–10.8 vs. 0–1.1 positive nodes, P<0.001) of lymph node metastases. Weaker associations were identified with the respective frequency of extrathyroidal extension (14–27% vs. 0–7%; P=0.018), distant metastasis (9–23% vs. 0%; P=0.011), and postoperative normalization of calcitonin (40–55% vs. 53–84%; P=0.012). On multivariate analysis, only lymph node metastases were associated with a less than 10-fold increase in preoperative calcitonin levels.

Conclusions: Based on these clinical data and preclinical literature, reduced responsiveness to stimulation with pentagastrin may reflect early dedifferentiation. Evidence of this condition may enable early risk stratification in patients with medullary thyroid cancer.


Key words: Calcitonin • Pentagastrin Stimulation • Medullary Thyroid Carcinoma • Extrathyroidal Growth • Lymph Node Metastasis • Distant Metastasis







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society